RadNet RDNT · NASDAQ
$69.27 +0.68% (+$0.47)
Summary
32 / 100 · Bulios Score
What speaks for it
- Revenue grew by 13% a year over the last 3 years.
- Analysts expect revenue to grow by 23% this fiscal year.
What to watch
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
- Repaying its net debt would take 4.3 years of operating profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 14% a year over 5 years. Over the last 3 years it grew by 13% a year. For the next fiscal year analysts expect revenue to grow by 23%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $21.1M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 9
- Hold 2
- Sell 0
Today's price within the analysts' price targets
The average target of $65 is 6.2% below today's price. 82% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Commercial Insurance1 59%
- Medicare1 25%
- Capitation Arrangements 6.5%
- Health Care, Other 3.4%
- Medicaid1 2.7%
- Other 3.8%
By region
- UNITED STATES 98%
- Non-US 1.7%
Commercial Insurance1 brings in 59% of revenue. Health Care, Other grew fastest, by 47% a year.
Segments in detail